Clinical Trial Update: Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating imatinib mesylate in patients with various activated tyrosine kinase-driven malignancies, including hypereosinophilic syndrome…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatofibrosarcoma Protuberans
• Hypereosinophilic Syndrome
• Myelomonocytic Leukemia
• Systemic Mastocytosis

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypereosinophilic Syndrome, Systemic Mastocytosis | Phase 2 | Status: COMPLETED